The global in-vitro inflammatory bowel disease diagnostic market size surpassed US$ 1.5 Bn in 2019 and to reach 2.4 billion by 2027 with a CAGR of 4% from 2020 to 2027.
Inflammatory bowel disease (IBD) is a terms used to describe disorders that involve chronic inflammation of the digestive tract. Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn's disease. Assays/biomarkers and analyzers are used to diagnose in-vitro inflammatory bowel disease. The rise in prevalence of inflammatory bowel disease and an increase in the demand for less-invasive, resource-benefit boost the global in-vitro inflammatory bowel disease diagnostic market. North America dominated the global in-vitro inflammatory bowel disease diagnostic market in 2019. The trend is anticipated to continue during the forecast period. High prevalence of diseases and well-established healthcare infrastructure enable proper diagnosis of IBD are responsible for high market share of the region.
Asia Pacific is expected to be a highly lucrative market for in-vitro inflammatory bowel disease diagnostic during the forecast period. Majority of countries in Asia Pacific are economically developing and numerous players are making significant investment in the region. These factors boost the market in Asia Pacific. The rise in technological advancements in countries in terms of healthcare and medical research is anticipated to fuel the market in the region.
High Prevalence of Inflammatory Bowel Disease (IBD) and Newer Biomarkers Offer Significant Opportunities
According to IBD Support Australia Incorporated, in 2015, around 61,000 people in Australia are affected by inflammatory bowel disease of which, around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis. Furthermore, according to New Zealand Ministry of Health more than 15,000 people are affected by IBD in New Zealand. New Zealand and Australia have a high prevalence of IBD in the world. Thus, rising cases of inflammatory bowel diseases boost the global market.
Major innovations in diagnostic technologies include the development of more sophisticated endoscopic and noninvasive techniques to improve the identification of complications, in particular, in malignant diseases associated with IBD. The future would see further progress in the identification of genetic susceptibility factors and of protein biomarkers and their use to describe the molecular epidemiology of IBD. It is expected that future diagnostics would include molecular parameters to detect early disease or guide therapies by predicting the individual course of disease.
In November 2016, Inova Diagnostics, announced the U.S Food and Drug Administration (FDA) clearance of QUANTA Lite Calprotectin Extended Range, an assay which aids in the diagnosis of Inflammatory Bowel Disease (IBD) and can help differentiate IBD from Irritable Bowel Syndrome (IBS).
Assays/Biomarker to Dominate Market
In terms of product, the global in-vitro inflammatory bowel disease diagnostic market has been divided into assays/biomarker and analyzers. The assays/biomarker segment has been further subdivided into calprotectin, lactoferrin, bile acids, H. pylori SA, pancreatic elastase, and others. The assays/biomarker segment dominated the global in-vitro inflammatory bowel disease diagnostic market in 2019. The trend is likely to continue during the forecast period, owing to an increase in cases of nerve pain and launch of new products.
In June 2019, Bühlmann Laboratories received 510(k) clearance from the U.S. Food and Drug Administration for its fCal Turbo calprotectin test, which is an immuno turbidimetric fecal calprotectin assay. fCAL turbo assay represents a high-throughput option to the company's recently FDA-cleared fCal ELISA assay.
Hospitals to be Promising End User
Based on end user, the global in-vitro inflammatory bowel disease diagnostic market has been classified into diagnostic laboratories, hospitals, and research institutes. The hospitals segment is expected to expand at a notable CAGR during the forecast period. The expansion of the segment can be attributed to a rise in the rate of hospitalization for inflammatory bowel diseases and a wide range of services offered by hospitals at a single site.
Growing Adoption of Biomarkers and Analyzers to Fuel Market Growth
The growing prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) in several regions of the world has played a key role in boosting the adoption of biomarkers and analyzers, which, in turn, is expected to propel the growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period. The demand for predictive biomarkers has witnessed consistent growth as the need to efficiently assess the mucosal disease activity in inflammatory bowel diseases has become imperative. Serum-based biomarkers have gained considerable traction across the global in-vitro inflammatory bowel disease diagnostics market in recent times and as per current observations, this trend is likely to provide a considerable push to the growth of the market for in-vitro inflammatory bowel disease diagnostics.
Demand to Remain Sluggish amid COVID-19 Pandemic
The healthcare sector has arguable remained one of the busiest core sectors during the ongoing COVID-19 pandemic, as researchers, scientists, and other stakeholders in the healthcare sector are increasingly focusing on discovering vaccines to contain the novel coronavirus. The progress in in-vitro inflammatory bowel disease diagnostics has remained relative slower. Although research and development activities are expected to continue during the ongoing pandemic, the adoption of in-vitro inflammatory bowel disease diagnostics is expected to remain sluggish, particularly in 2020 due to the fear among patients pertaining to contracting the novel coronavirus in hospitals.
North America to Dominate Global Market
The global in-vitro inflammatory bowel disease diagnostic market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2019, followed by Europe. North America accounted for a major share of the global in-vitro inflammatory bowel disease diagnostic market in 2019, owing to rise in the rate of adoption of new technology for detection of diseases and an increase in the number of various disorders. The in-vitro inflammatory bowel disease diagnostic market in Asia Pacific is anticipated to expand at a higher CAGR from 2020 to 2030. The expansion of the in-vitro inflammatory bowel disease diagnostic market in the region can be attributed to a rise in prevalence of disorders and an increase in awareness about diagnosis in the region.
Competition Landscape
DiaSorin S.p.A, BÜHLMANN Laboratories AG, and F. Hoffmann-La Roche AG are leading players operating in the global in-vitro inflammatory bowel disease diagnostic market and hold majority market share. The global in-vitro inflammatory bowel disease diagnostic market is fragmented in terms of number of players. Key players in the global market include DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott, Quidel Corporation, American Laboratory Products Company (ALPCO), Certest Biotec SL., and Biosystems S.A. New product development through robust R&D activities and mergers & acquisitions are key strategies adopted by these players to operate their business in the global in-vitro inflammatory bowel disease diagnostic market.
Market Segmentation
By Product
By End User
By Region
Scope of the Report
VRR’s report on the global in-vitro inflammatory bowel disease diagnostic market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global in-vitro inflammatory bowel disease diagnostic market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global in-vitro inflammatory bowel disease diagnostic market from 2020 to 2027.
The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global in-vitro inflammatory bowel disease diagnostic market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global in-vitro inflammatory bowel disease diagnostic market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global in-vitro inflammatory bowel disease diagnostic market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global in-vitro inflammatory bowel disease diagnostic market.
The report also delves into the competition landscape of the global in-vitro inflammatory bowel disease diagnostic market. Key players operating in the global in-vitro inflammatory bowel disease diagnostic market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global in-vitro inflammatory bowel disease diagnostic market that have been profiled in this report.
Key Questions Answered
Research Objectives and Research Approach
The comprehensive report on the global in-vitro inflammatory bowel disease diagnostic market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global in-vitro inflammatory bowel disease diagnostic market in terms of product, end user, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global in-vitro inflammatory bowel disease diagnostic market.
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers